预约演示

更新于：2026-06-18

Bevacizumab

贝伐珠单抗

更新于：2026-06-18

概要

基本信息

药物类型

单克隆抗体

别名

Bevacizumab(Genetical Recombination)、rhuMAb-VEGF、贝伐单抗

+ [17]

靶点

VEGF-A

作用方式

抑制剂

作用机制

VEGF-A抑制剂(血管内皮生长因子A抑制剂)、血管生成抑制剂

治疗领域

肿瘤神经系统疾病消化系统疾病+ [9]

在研适应症

不可切除的肝细胞癌肝细胞癌复发性胶质母细胞瘤+ [184]

非在研适应症

异戊酸血症急性嗜碱性粒细胞白血病急性嗜酸细胞白血病+ [307]

原研机构

Genentech, Inc.

在研机构

The University of Texas MD Anderson Cancer Center

National Cancer Institute

Bristol Myers Squibb Co.

+ [28]

非在研机构

Eli Lilly & Co.

Novartis Pharmaceuticals Corp.

Northwestern University

+ [53]

权益机构

Roche Korea Co., Ltd.

Immune-Onc Therapeutics, Inc.

Roche Holding AG

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2004-02-26),

结肠癌直肠癌

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

Sequence Code 41632H

来源: *****

Sequence Code 41637L

来源: *****

关联

3,568

项与贝伐珠单抗相关的临床试验

NCT07274787

/ Not yet recruitingN/AIIT

An Open Label, Prospective, Pilot Study To Evaluate The Safety And Effectiveness Of The NaviFUS System In Conjunction With A Standard Treatment Regimen Of Bevacizumab (BEV) In Patients With Recurrent Glioblastoma

This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.

开始日期2026-12-01

申办/合作机构

NaviFUS Corp.

NCT07504588

/ Not yet recruiting临床2期IIT

A Randomized Phase II Trial of Sacituzumab Govitecan (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.

开始日期2026-09-10

申办/合作机构

National Cancer Institute

NCT07637851

/ Not yet recruiting临床1/2期IIT

A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer With Poor Response to First-Line Chemotherapy

The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are:
* What is the safety profile of ubamatamab when administered with carboplatin-paclitaxel ± bevacizumab?
* What is the objective response rate after three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab?
Participants will:
* Receive three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab, followed by maintenance therapy with ubamatamab ± bevacizumab for up to 15 months, depending on HRD status and disease response after the initial treatment cycles.
* Attend regular clinic visits throughout the treatment period for checkups and tests

开始日期2026-08-01

申办/合作机构

Arcagy-Gineco

[+1]

100 项与贝伐珠单抗相关的临床结果

登录后查看更多信息

100 项与贝伐珠单抗相关的转化医学

登录后查看更多信息

100 项与贝伐珠单抗相关的专利（医药）

登录后查看更多信息

18,344

项与贝伐珠单抗相关的文献（医药）

2026-12-31·mAbs

A novel insulin-like growth factor II-based masking domain for conditional activation of therapeutic antibodies

Article

作者: Shi, Lihua ; Cho, Minseon ; Nishida, Motohiko ; Chiu, Mark L. ; Zhang, Di

Systemic target engagement constrains the therapeutic index of many antibody drugs, particularly in inflammatory disease and immuno-oncology. Protease-cleavable masking can localize activity to disease sites, but existing approaches often tradeoff masking strength, reversibility, and developability. Here, we evaluated the insulin-like growth factor II (IGF-II) as a compact, structurally defined steric masking domain for protease-dependent conditional activation of therapeutic antibodies. IGF-II masking domains, including a receptor-silent variant (IGF-II-s), were engineered as N-terminal fusions to therapeutic antibodies via protease-cleavable linkers and characterized using antigen-binding and cell-based functional assays. IGF-II masking attenuated anti-TNFα binding and neutralization potency in a protease-dependent manner and activity was largely restored following cleavage. In vivo, an MMP2/9-cleavable masked anti-TNFα antibody retained efficacy comparable to adalimumab and infliximab in a collagen antibody-induced arthritis model, yet, unlike the reference antibodies, did not measurably reduce survival in a Listeria monocytogenes infection challenge model at the dose tested. IGF-II-s showed no detectable IGF receptor binding and provided stronger masking than native IGF-II. This generalized approach was demonstrated across multiple antibodies, enabling efficient protease-dependent conditional activation of trastuzumab (anti-HER2), an anti-IL-1β antibody, and bevacizumab (anti-VEGF). Together, these results established an engineered IGF-II-based masking domain as a versatile, IGF-II receptor-silent platform enabling protease-dependent conditional activation of therapeutic antibodies, with potential to improve safety and expand therapeutic windows.

2026-12-31·mAbs

Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection

Article

作者: Gillard, Marianne ; Marcellin, Esteban ; Gunter, Helen ; Chavalparit, Thornwit ; Barry, Craig ; Mercer, Timothy

Messenger RNA (mRNA) has emerged as a powerful tool for protein expression in clinical settings, yet its potential as a platform for biologics manufacturing remains underexplored. Here, we evaluate transient mRNA transfection in Chinese hamster ovary (CHO) cells as a rapid and versatile system for protein production. Using reporter mRNAs, we optimize transfection efficiency and benchmark performance against industry-standard plasmid transfection and stable cell line methods. We demonstrate that co-transfection of heavy and light chain mRNAs enables the efficient synthesis, assembly and secretion of the monoclonal antibody bevacizumab with high fidelity. Compared to conventional approaches, mRNA transfection drives rapid and predictable protein expression, reducing cell incubation times and enabling sequential or conditional expression. These features highlight mRNA as a flexible and efficient platform for transient expression, providing a foundation for accelerating the development and manufacturing of biologics.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia

Article

作者: Chaiyakunapruk, Nathorn ; Patikorn, Chanthawat ; Sulaiman Shah, Audi Adawiah ; Wong, Yoke Fui ; Mohamed, Rosmawati

AIM:

This study aims to evaluate the cost-effectiveness of atezolizumab plus bevacizumab as first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) in Malaysia, compared with the current standard treatments in the Malaysian Ministry of Health (MOH) to inform public healthcare decision‑making.

MATERIALS AND METHODS:

A cost-effectiveness analysis was conducted from the MOH perspective, following the national pharmacoeconomic guidelines (2019). The study compared atezolizumab plus bevacizumab with sorafenib and lenvatinib, respectively, using a partitioned survival model to project health outcomes and costs over a lifetime horizon. Clinical efficacy data were sourced from published trials and network meta-analyses. Cost inputs reflected local healthcare resource use and prices, using 2024 Malaysian Ringgit values inflated via the Consumer Price Index for Health. Costs and outcomes were discounted at 3% annually. Deterministic and probabilistic sensitivity analyses were performed to assess the impact of key parameter uncertainties on the results.

RESULTS:

Atezolizumab plus bevacizumab provided the highest quality-adjusted life years (QALYs) and life years compared to sorafenib and lenvatinib. Sorafenib was dominated by lenvatinib due to lower QALYs and higher costs and excluded from further analysis. Compared to lenvatinib, atezolizumab plus bevacizumab yielded 0.873 additional QALYs and RM 44,863 additional cost, resulting in an incremental cost-effectiveness ratio (ICER) of RM 51,399 per QALY gained (∼0.906 GDP/capita at Malaysia's 2024 GDP/capita RM 56,734).

CONCLUSIONS:

Atezolizumab plus bevacizumab is cost-effective compared to lenvatinib and sorafenib across willingness-to-pay (WTP) values of one to three times Malaysia's GDP per capita. These findings provide evidence to inform public health policy that expanding funding and adoption of atezolizumab plus bevacizumab is likely to improve health outcomes cost-effectively.

4,882

项与贝伐珠单抗相关的新闻（医药）

23 小时之前

·PRNewswire

Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress

SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) in cervical cancer at the European Society for Medical Oncology Gynaecological Cancers Congress 2026 (ESMO Gynae 2026) in Copenhagen, Denmark, held June 17–19, 2026. The two studies demonstrated that 9MW2821 has a manageable safety profile and promising therapeutic effects in patients with cervical cancer, with particularly notable survival benefits observed in immunotherapy-pretreated patients. The combination of 9MW2821 with a PD-1 inhibitor showed encouraging antitumor activity in advanced cervical cancer. Continue Reading Prof. Yang Huijuan from Fudan University Shanghai Cancer Center delivered an in-depth oral presentation on behalf of the research team. Oral Presentation: BFv in Recurrent or Metastatic Cervical Cancer The Phase I/II cervical cancer cohort of this clinical study (NCT05216965) enrolled patients with recurrent or metastatic cervical cancer (r/m CC) who had progressed on or after platinum-based chemotherapy with or without bevacizumab and received no more than 2 previous systemic regimens for recurrent or metastatic disease. Subjects received 1.25 mg/kg of BFv by intravenous infusion on days 1, 8, and 15 each 28-day cycle. As of March 20, 2025, 55 patients were enrolled. Of these, 49.09% patients had received prior platinum-based doublet chemotherapy plus bevacizumab, and 58.18% had received prior platinum-based doublet chemotherapy plus immune checkpoint inhibitors. Among the 53 patients evaluable for efficacy, the confirmed objective response rate (cORR) and disease control rate (DCR) were 32.08% and 81.13%, respectively, with 1 complete response (1.87%) and 17 partial responses (30.19%). Median progression-free survival (mPFS) was 3.9 months and median duration of response (mDOR) was 5.98 months. Median overall survival (mOS) was 19.4 months, with a 12-month OS rate of 72.7% and a 24-month OS rate of 49.1%. Among the 31 post-IO patients evaluable for efficacy, cORR and DCR were 29.00% and 77.40%, respectively. Median PFS was 4.0 months and median DoR was 9.1 months. Median OS has not yet been reached. The 12-month OS rate was 76.6% and the 24-month OS rate was 51.1%. No new safety signals were observed in this follow-up. Poster Presentation: BFv in Combination with Toripalimab for Recurrent or Metastatic Cervical Cancer The study consists of a phase lb safety run-in followed by a phase lI cohort expansion, enrolling patients with cervical cancer who had received ≥ 1 line therapy (Phase lb), and who had no prior systemic chemotherapy (Phase ll). Patients received BFv 1.25mg/kg on days 1, 8 and Toripalimab at 240mg on day 1 of each 21-days cycle. The primary endpoints were safety and preliminary efficacy. As of March 19, 2026, a total of 19 patients were enrolled, including 3 previously treated patients and 16 treatment-naïve patients. The mean patient age was 57.8 years, and 89.5% had squamous cell carcinoma. 13 patients were evaluable for efficacy with at least one post-baseline tumor assessment. The ORR was 76.9% (10/13), including 1 complete response (CR) and 9 partial responses (PR), and the DCR was 100%. In treatment-naïve patients, the ORR reached 80.0% (8/10). Treatment-related adverse events (TRAEs) were primarily Grade 1–2, and no new safety signals were observed. The preliminary findings demonstrate a synergistic effect of the Nectin-4-targeting ADC combined with a PD-1 inhibitor in the treatment of cervical cancer, and also offer the potential to establish a new first-line therapy for patients with recurrent or metastatic cervical cancer. About 9MW2821 (BFv) 9MW2821 is a novel Nectin-4-targeting ADC independently developed by Mabwell based on its ADC development platform. It is the world's first Nectin-4 ADC to enter Phase III clinical trials for cervical cancer (CC) and triple-negative breast cancer (TNBC). Four pivotal Phase III clinical studies are underway. 9MW2821 has obtained FDA Fast Track Designation for three indications, Orphan Drug Designation for one indication, and Breakthrough Therapy Designation from the CDE of NMPA for two indications. Interim analysis for the Phase III clinical trials of urothelial carcinoma (UC) monotherapy, UC combination therapy and CC monotherapy are planned to be conducted in 2026, and Applications for pre-NDA meetings are expected to be submitted to the Center for Drug Evaluation under the National Medical Products Administration based on the data of interim analysis. About Mabwell Mabwell (688062.SH, 02493.HK) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell's mission is "Explore Life, Benefit Health" and its vision is "Innovation, from Ideas to Reality." For more information, please visit . Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms. Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results. The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement. SOURCE Mabwell 21% more press release views with Request a Demo

快速通道临床结果临床3期孤儿药免疫疗法

2026-06-18

·PRNewswire

TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026

Objective response rate across all 29 participants was 32.1%; Favorable disease control rate (92.9%) across all participants was observed Data suggest that the combination of Ixo-V and bevacizumab may expand therapeutic options for Claudin 6-positive patients in both the platinum-resistant and platinum-sensitive settings Pivotal data from the Phase 2 registrational CATALINA-2 study anticipated in mid-2027 LOS ANGELES, June 18, 2026 /PRNewswire/ -- TORL BioTherapeutics LLC (TORL), a clinical stage oncology-focused biotechnology company, today announced preliminary Phase 1 safety and efficacy data of ixotatug vedotin (Ixo-V or TORL-1-23) in combination with bevacizumab in recurrent ovarian cancer at the European Society of Medical Oncology (ESMO) Gynaecological Cancers Congress 2026. The data presented suggest that the combination of Ixo-V and bevacizumab may expand therapeutic options for patients with Claudin 6 -positive (CLDN6+) ovarian cancer in both the platinum-resistant and platinum-sensitive settings. "We are encouraged by the emerging safety and efficacy profile of Ixo-V in combination with bevacizumab in patients with CLDN6-positive recurrent ovarian cancer, a population with particularly poor prognosis and high unmet need," said Aran Maree, M.D., Chief Executive Officer of TORL BioTherapeutics. "In parallel with our registrational study, CATALINA-2, these data provide important clinical support for Ixo-V in combination with existing standards of care, such as bevacizumab, and in earlier lines of ovarian cancer." As a part of the ongoing Phase 1 first-in-human, dose-escalation study evaluating the safety, efficacy, and antitumor activity of Ixo-V in patients with advanced cancer, the combination of Ixo-V with bevacizumab is being assessed in patients with CLDN6+ and CLDN6-low recurrent ovarian cancer (greater than 30% or 1-30% tumor cell membrane staining of any intensity by immunohistochemistry, respectively). Data presented reflect Ixo-V (2.4 mg/kg or 3.0 mg/kg) plus bevacizumab (15 mg/kg) administered intravenously on day one and pegfilgrastim on day four of a 21-day cycle. A total of 29 patients were treated, and 18 remain on treatment. Patients had received a median of two prior lines of therapy (range: 1-5). Prior treatments included platinum-based chemotherapy, taxanes, bevacizumab, PARP inhibitors, and mirvetuximab soravtansine. Per RECIST v1.1 criteria, preliminary results suggest that the combination of Ixo-V and bevacizumab may expand therapeutic options for patients with CLDN6+ ovarian cancer in both the platinum-resistant and platinum-sensitive settings. Key study findings include the following: Preliminary results showed favorable tolerability characterized by a manageable safety profile, with no clinically significant bleeding, ocular events, bowel perforation, or thromboembolic events reported. The objective response rate (ORR) across all 29 participants was 32.1%, with ORRs of 33.3% in the 2.4 mg/kg cohort and 31.3% in the 3.0mg/kg. The disease control rate (DCR) across all participants was 92.9%, including 83.3% in the 2.4 mg/kg cohort and 100% in the 3.0mg/kg cohort. Clinical responses were observed in patients who received prior PARP inhibitors (7 of 13), prior bevacizumab (5 of 20), or prior mirvetuximab soravtansine (1 of 1). Presentation Details Title: Preliminary safety and efficacy of ixotatug vedotin (TORL-1-23), a Claudin 6-targeted ADC, in combination with bevacizumab in recurrent ovarian cancer Lead Author: Jung-Yun Lee, M.D., Ph.D., Department of Obstetrics and Gynecology, Yonsei University College of Medicine Presentation Number: 140P Presentation Session: Poster Display Session Presentation Session Date and Time: Thursday, June 18, 2026; 12:45-13:30 CEST TORL continues to advance CATALINA-2, a global, randomized, open-label Phase 2 study of Ixo-V in women with CLDN6+ platinum-resistant ovarian cancer, with topline pivotal results anticipated in mid-2027. In parallel to this registrational program, CATALINA-4, a Phase 1b/2 study to investigate the safety and efficacy of Ixo-V with chemotherapy given before initial surgery in women with CLDN6+ advanced stage ovarian cancer, is ongoing. Beyond ovarian cancer, the Company continues to evaluate Ixo-V in other indications including non-small cell lung cancer. About Claudin 6 Claudin 6 (CLDN6) is overexpressed in several cancers with limited to no detectable expression observed in normal tissues, making it an ideal target for ADC development. CLDN6 is a transmembrane protein and member of a family of proteins important for cell-to-cell connectivity in normal tissues. CLDN6 expression normally occurs during embryonic and fetal development but not in adult tissues. Overexpression of CLDN6 occurs in specific malignancies and has been implicated in the pathogenesis of certain cancers including ovarian, non-small cell lung, endometrial and testicular malignancies. High expression correlates with shortened survival outcomes for patients with ovarian cancer. About Ixotatug Vedotin (Ixo-V; TORL-1-23) Ixotatug vedotin is a first- and potentially best-in-class clinical-stage ADC for the treatment of CLDN6+ solid tumors. Ixotatug vedotin has received Fast Track Designation from the U.S. Food and Drug Administration. TORL BioTherapeutics is currently enrolling the pivotal Phase 2 CATALINA-2 study of ixotatug vedotin in women with CLDN6+ PROC. Further details can be found at . About CATALINA-2 CATALINA-2 is a global, randomized, open-label Phase 2 study of novel CLDN6-targeted ADC ixotatug vedotin in women with CLDN6+ PROC who have received one to three prior lines of therapy. The primary endpoint is objective response rate (ORR) per RECIST v1.1 by blinded independent central review. Secondary endpoints consist of duration of response, ORR by investigator assessment, progression-free survival, overall survival and safety. Further details can be found at . About TORL BioTherapeutics LLC TORL is a clinical-stage biopharmaceutical company developing new antibodies, both monoclonal antibodies and ADCs, with the goal of transforming the lives of patients challenged with a variety of human malignancies. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for new, promising and novel cancer targets. SOURCE TORL Biotherapeutics LLC 21% more press release views with Request a Demo

临床1期临床结果快速通道临床2期

2026-06-18

·ioncology

2026 ESMO GI重磅口头摘要抢先看，多瘤种诊疗新数据全面来袭

点击蓝字关注我们编者按 2026年欧洲肿瘤内科学会胃肠道肿瘤大会（ESMO GI 2026）将于7月1~4日在德国慕尼黑线下召开，并同步开启线上虚拟会议通道，汇聚全球胃肠肿瘤领域顶尖专家、临床研究者与医务工作者，聚焦胃肠肿瘤预防、诊断、综合治疗全链条的前沿进展。本届大会设置多学科病例研讨、临床争议辩论、重磅研究口头汇报等丰富学术环节，内容覆盖早期筛查、生物标志物导向精准治疗、系统治疗创新、患者生活质量管理等多个核心方向，是洞悉全球胃肠肿瘤诊疗发展趋势、交流临床实战经验的顶级学术平台。本次我们整理大会优选口头报告（Proffered Paper）与快速口头报告（Rapid oral session）核心摘要，聚焦肝癌、结直肠癌、胰腺癌、胆道肿瘤、胃食管肿瘤等主流瘤种，带大家提前解锁多项重磅临床研究成果，一睹全球胃肠肿瘤领域的最新突破。一、创新专题快速口头报告专场（7月4日08:30~10:00丨13a会议室）本场由Lorenza Rimassa、Andres Cervantes、Manuel Salto-Tellez担任主席，聚焦靶向新药、联合方案、生物标志物检测等创新方向，多项Ⅱ期、Ⅲ期及探索性研究集中亮相，覆盖胰腺癌、结直肠癌、胃食管肿瘤、胆管癌等多个瘤种。摘要号：LBA4 英文标题：TRIPP-FFX: Results of an open-label, multi-centre, randomized study of TaRgeted Intratumoural Placement of Phosphorous-32 microparticles in addition to FOLFIRINOX versus FOLFIRINOX alone in patients with unresectable locally advanced pancreatic cancer (uLAPC)中文标题：TRIPP-FFX研究：局部晚期不可切除胰腺癌患者采用磷-32微粒瘤内靶向给药联合FOLFIRINOX方案对比单用FOLFIRINOX方案的一项开放标签、多中心随机研究结果讲者：Michele Milella (Verona, Italy) 摘要号：6RO 英文标题：Calderasib (MK-1084) for KRAS G12C-mutated (mut) advanced colorectal cancer (CRC): Results from KANDLELIT-001中文标题：Calderasib（MK-1084）治疗KRAS G12C突变型晚期结直肠癌：KANDLELIT-001研究结果讲者：Rafal Dziadziuszko (Gdansk, Poland) 摘要号：495RO 英文标题：HERIZON-GEA-01: Exploratory analysis of response characteristics and PFS2 in advanced or metastatic gastroesophageal adenocarcinoma (mGEA)中文标题：HERIZON-GEA-01研究：晚期/转移性胃食管腺癌疗效特征与PFS2的探索性分析讲者：Filippo Pietrantonio (Milan, Italy) 摘要号：343RO 英文标题：Fanregratinib in fibroblast growth factor receptor 2 (FGFR2)- fusions/rearrangements intrahepatic cholangiocarcinoma (ICC): Pivotal part of a phase II trial中文标题：Fanregratinib治疗成纤维细胞生长因子受体2（FGFR2）融合/重排型肝内胆管癌：一项Ⅱ期关键性研究结果讲者：Jianming Xu (Beijing, China) 摘要号：344RO 英文标题：A phase I study of futibatinib in combination with zimberelimab and chemotherapy in first-line unresectable advanced or metastatic biliary tract cancer中文标题：Futibatinib联合Zimberelimab及化疗一线治疗不可切除晚期/转移性胆道肿瘤的Ⅰ期临床研究讲者：Kazuyoshi Ohkawa (Osaka, Japan) 摘要号：345RO 英文标题：Precemtabart tocentecan (Precem-TcT) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Results from the Phase Ib/II PROCEADE-PanTumor PDAC substudy中文标题：Precemtabart Tocentecan治疗转移性胰腺导管腺癌：Ⅰb/Ⅱ期PROCEADE泛肿瘤研究胰腺腺癌亚组结果讲者：Zev A. Wainberg (Los Angeles, United States of America) 摘要号：7RO 英文标题：Molecular correlates of enhanced outcome with first-line (1L) encorafenib + cetuximab (EC) ± mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BREAKWATER study中文标题：BREAKWATER研究：Encorafenib联合西妥昔单抗±mFOLFOX6一线治疗BRAF V600E突变转移性结直肠癌疗效获益的分子关联因素分析讲者：Scott Kopetz (Houston, United States of America) 摘要号：496RO 英文标题：Interchangeability of PD-L1 assays and scoring methods in gastroesophageal adenocarcinoma: The EORTC ASPIRE project中文标题：胃食管腺癌中不同PD-L1检测平台及评分体系的互通性研究：EORTC ASPIRE项目讲者：Angelica Petrillo (Naples, Italy) 二、快速口头报告专场（7月4日16:15~17:10）本时段报告内容丰富，横跨肝癌真实世界研究、转移性结直肠癌全程管理、dMMR/MSI型肿瘤新辅助免疫、局部进展期直肠癌综合治疗、结直肠癌肝转移局部治疗等热门领域，兼顾真实世界数据、随机对照研究与临床策略探索，报告结束后设置专场点评与互动问答环节。摘要号：184RO 英文标题：Real-world data from PROACTIF: Overall survival of hepatocellular carcinoma patients with large tumors or portal vein thrombosis treated with selective internal radioembolization therapy with yttrium-90中文标题：PROACTIF真实世界研究：钇-90选择性内放射栓塞治疗巨块型或合并门静脉癌栓肝细胞癌患者的总生存期数据讲者：Boris Guiu (Montpellier, France) 摘要号：2RO 英文标题：Cetuximab in the continuum of care of molecularly selected metastatic colorectal cancer: The CAPRI-2 GOIM trial中文标题：分子筛选人群中转移性结直肠癌全程管理中西妥昔单抗的应用：CAPRI-2 GOIM研究讲者：Giulia Martini (Napoli, Italy) 摘要号：3RO 英文标题：Treatment strategy and immune-related toxicity shape response to neoadjuvant immunotherapy in dMMR/MSI colorectal cancer: Results from the AGEO-NEO-MSI study中文标题：治疗方案与免疫相关毒性对dMMR/MSI型结直肠癌新辅助免疫治疗疗效的影响：AGEO-NEO-MSI研究结果讲者：Annalice Gandini (Paris, France) 摘要号：4RO 英文标题：Chemotherapy (CT) plus anti-EGFR retreatment versus CT switch plus anti-VEGF/R after progression in pMMR/MSS, RAS/BRAF wild-type metastatic colorectal cancer (mCRC): Individual patient data analysis of 5 randomized trials (RCTs).中文标题：pMMR/MSS、RAS/BRAF野生型转移性结直肠癌进展后，化疗联合再次使用抗EGFR方案对比更换化疗联合抗血管生成方案：五项随机对照试验的个体患者数据汇总分析讲者：Vittorio Studiale (Pisa, Italy) 摘要号：295RO 英文标题：Immunotherapy based total neoadjuvant therapy with or without short-course radiotherapy for locally advanced rectal cancer: Updated results of TORCH-iTNT中文标题：基于免疫治疗的全程新辅助治疗联合/不联合短程放疗治疗局部进展期直肠癌：TORCH-iTNT研究更新结果讲者：Zhen Zhang (Shanghai, China) 摘要号：5RO 英文标题：LAVA-CRLM: Randomised phase II trial of microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases.中文标题：LAVA-CRLM研究：微波消融对比立体定向放疗治疗结直肠癌寡转移性肝转移的随机Ⅱ期临床研究讲者：Signe L. Risumlund (Copenhagen, Denmark) 三、大会优选口头报告专场（7月2日14:00~15:30丨14会议室）本场由Eric Van Cutsem、Teresa Macarulla担任主席，核心聚焦肝细胞癌与胰腺癌两大难治性瘤种，多项Ⅲ期重磅研究公布总生存期、安全性、有效性数据，为介入联合系统治疗、靶向联合化疗方案的临床应用提供高级别证据。摘要号：LBA2 英文标题：Tumour response analyses by RECIST v1.1 and mRECIST in the Phase 3 EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib plus transarterial chemoembolisation (TACE) in embolisation-eligible hepatocellular carcinoma (eeHCC)中文标题：Ⅲ期EMERALD-3研究：曲美木单抗联合度伐利尤单抗±仑伐替尼联合经动脉化疗栓塞（TACE）治疗适合栓塞的肝细胞癌，基于RECIST v1.1与mRECIST标准的肿瘤疗效分析讲者：Joseph P. Erinjeri (New York, United States of America) 摘要号：183O 英文标题：Overall survival (OS) in EMERALD-1: a Phase 3 study of durvalumab (D) + bevacizumab (B) and transarterial chemoembolisation (TACE) in participants (pts) with unresectable embolisation-eligible hepatocellular carcinoma (eeHCC)中文标题：Ⅲ期EMERALD-1研究：度伐利尤单抗联合贝伐珠单抗+经动脉化疗栓塞治疗不可切除且适合栓塞的肝细胞癌患者的总生存期结果讲者：Bruno Sangro (Pamplona – Madrid, Spain) 摘要号：340O 英文标题：Safety and efficacy of zoldonrasib (RMC-9805) plus chemotherapy in patients (Pts) with 1L RAS G12D metastatic pancreatic adenocarcinoma (mPDAC)中文标题：Zoldonrasib（RMC-9805）联合化疗一线治疗RAS G12D突变转移性胰腺导管腺癌的安全性与有效性讲者：Brian M. Wolpin (Boston, United States of America) 摘要号：341O 英文标题：Safety and efficacy of zoldonrasib (RMC-9805) plus daraxonrasib (RMC-6236) in patients with 2L+ KRAS G12D metastatic pancreatic adenocarcinoma (mPDAC)中文标题：Zoldonrasib（RMC-9805）联合Daraxonrasib（RMC-6236）二线及以上治疗KRAS G12D突变转移性胰腺导管腺癌的安全性与有效性讲者：Nilofer S. Azad (Baltimore, United States of America) 摘要号：342O 英文标题：Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+ metastatic pancreatic adenocarcinoma (mPAC): Phase II GLEAM study中文标题：Zolbetuximab联合吉西他滨+白蛋白结合型紫杉醇治疗CLDN18.2阳性转移性胰腺腺癌：Ⅱ期GLEAM研究结果讲者：Wungki Park (New York, United States of America) 四、大会优选口头报告专场（7月3日16:30~18:00丨14会议室）本场由Michel P. Ducreux、Jeeyun Lee担任主席，围绕结直肠癌术后辅助治疗、KRAS突变结直肠癌二线治疗、胃食管腺癌一线方案、患者生活质量等方向展开，同时探索ctDNA在结直肠癌肝转移术后的指导价值，兼顾疗效评估、治疗策略优化与人文关怀。摘要号：8O 英文标题：ctDNA status and adjuvant chemotherapy after resection of colorectal liver metastases: an overall survival analysis of the GALAXY study中文标题：结直肠癌肝转移切除术后ctDNA状态与辅助化疗的价值：GALAXY研究总生存期分析讲者：Kozo Kataoka (Nishinomiya, Japan) 摘要号：LBA1 英文标题：Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: results from the KRYSTAL-10 trial中文标题：Adagrasib联合西妥昔单抗对比化疗二线治疗KRAS G12C突变转移性结直肠癌：KRYSTAL-10研究结果讲者：Josep Tabernero (Barcelona, Spain) 摘要号：1O 英文标题：ATOMIC (A021502/AIO-KRK-0317): Does duration of adjuvant chemotherapy (chemo) or immunotherapy matter?中文标题：ATOMIC研究（A021502/AIO-KRK-0317）：辅助化疗与辅助免疫治疗的疗程长短是否影响疗效？讲者：Anke Reinacher-Schick (Bochum, Germany)特邀点评专家：Per Pfeiffer（丹麦欧登塞）问答与讨论：17:10-17:20 摘要号：493O 英文标题：STAR-221: A phase 3 study of first-line (1L) domvanalimab (D), zimberelimab (Z), and chemotherapy (chemo) vs nivolumab (N) + chemo in advanced HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC)中文标题：Ⅲ期研究STAR-221研究：Domvanalimab联合Zimberelimab+化疗对比纳武利尤单抗+化疗一线治疗HER2阴性晚期胃、胃食管结合部及食管腺癌讲者：Sun Young Rha (Seoul, Republic of Korea) 摘要号：494O 英文标题：Health-related quality of life (HRQoL) with zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Results from HERIZON-GEA-01中文标题：HERIZON-GEA-01研究：Zanidatamab联合化疗±替雷利珠单抗一线治疗HER2阳性晚期/转移性胃食管腺癌的健康相关生活质量分析讲者：Kohei Shitara (Kashiwa, Japan) 作为全球胃肠肿瘤领域的标杆学术会议，2026 ESMO GI汇聚了全球前沿临床研究成果，本次公示的口头摘要覆盖精准靶向、免疫联合、介入治疗、局部消融、术后辅助、全程管理、生活质量等全维度内容，既有真实世界数据印证经典方案价值，也有新型药物、创新联合疗法、检测技术的突破性探索。从肝癌介入联合免疫的持续优化，到结直肠癌基于分子分型的分层治疗；从胰腺癌、胆管癌小众靶点新药突围，再到胃食管肿瘤免疫双抗、抗体偶联药物的临床验证，一系列研究或将重塑临床诊疗格局。后续我们也将持续跟进本届大会现场解读、专家点评及研究深度分析，第一时间传递全球胃肠肿瘤诊疗新动向，敬请持续关注！（来源：肿瘤瞭望消化时讯）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

100 项与贝伐珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06409	贝伐珠单抗	L01XC07	DB00112

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
不可切除的肝细胞癌	日本	Chugai Pharmaceutical Co., Ltd.	2020-09-25
肝细胞癌	美国	Genentech, Inc.	2020-05-29
复发性胶质母细胞瘤	美国	Genentech, Inc.	2020-05-29
复发性原发性腹膜癌	美国	Genentech, Inc.	2014-11-14
卵巢癌	日本	Chugai Pharmaceutical Co., Ltd.	2013-11-22
胶质瘤	日本	Chugai Pharmaceutical Co., Ltd.	2013-06-14
乳腺癌	日本	Chugai Pharmaceutical Co., Ltd.	2011-09-26
结直肠癌	日本	Chugai Pharmaceutical Co., Ltd.	2009-09-18
转移性肾细胞癌	美国	Genentech, Inc.	2009-07-31
胶质母细胞瘤	美国	Genentech, Inc.	2009-05-05
转移性结直肠癌	美国	Genentech, Inc.	2009-05-05
节细胞神经胶质瘤	日本	Chugai Pharmaceutical Co., Ltd.	2007-04-18
非鳞状非小细胞肺癌	美国	Genentech, Inc.	2006-10-11
输卵管癌	欧盟	Roche Registration GmbH	2005-01-12
输卵管癌	冰岛	Roche Registration GmbH	2005-01-12
输卵管癌	列支敦士登	Roche Registration GmbH	2005-01-12
输卵管癌	挪威	Roche Registration GmbH	2005-01-12
转移性乳腺癌	欧盟	Roche Registration GmbH	2005-01-12
转移性乳腺癌	冰岛	Roche Registration GmbH	2005-01-12
转移性乳腺癌	列支敦士登	Roche Registration GmbH	2005-01-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期子宫内膜癌	临床3期	美国	National Cancer Institute	2026-01-27
复发性子宫内膜癌	临床3期	美国	National Cancer Institute	2026-01-27
晚期头颈癌	临床3期	美国	National Cancer Institute	2023-03-13
头颈癌转移	临床3期	美国	National Cancer Institute	2023-03-13
局部晚期头颈部皮肤鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
鼻咽癌	临床3期	美国	National Cancer Institute	2023-03-13
鼻咽鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
口咽肿瘤	临床3期	美国	National Cancer Institute	2023-03-13
复发性咽部鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
复发性头颈部鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05537402 (LOST-B, CTgov)	临床2期	肝细胞癌	1	Atezolizumab+Bevacizumab (Arm A: Atezolizumab and Bevacizumab)	襯製鏇鬱製鹹積鹹築襯(遞範壓壓範餘鏇壓鏇淵) = 築糧遞蓋膚衊餘鏇築膚壓齋艱築願繭範壓衊憲 (艱鹽壓製齋築鏇鹹觸繭, 鬱壓鏇餘鏇觸遞獵遞憲 ~ 繭觸顧廠積鹽膚獵範艱) 更多	-	2026-06-18
NCT05537402 (LOST-B, CTgov)	临床2期	肝细胞癌	1	transarterial chemoembolization (TACE) or transarterial radioembolization (TARE (Arm B: Locoregional Therapy With TACE or TARE)	襯製鏇鬱製鹹積鹹築襯(遞範壓壓範餘鏇壓鏇淵) = 鬱鬱糧範構壓遞網製遞壓齋艱築願繭範壓衊憲 (艱鹽壓製齋築鏇鹹觸繭, 齋繭鑰製製襯鬱觸網壓 ~ 餘膚鹹蓋廠獵膚夢壓製) 更多	-	2026-06-18
NCT04829383 (BTCRC-GI20-457 \| AB7, CTgov)	临床2期	不可切除的肝细胞癌	6	Atezolizumab+Bevacizumab	獵艱餘簾夢簾積蓋築獵 = 齋構淵顧壓願遞觸製鏇壓簾糧遞積願齋餘襯願 (觸選淵淵壓窪淵襯蓋淵, 艱壓膚築廠積選築襯鏇 ~ 築鹽鬱淵醖餘願餘廠齋) 更多	-	2026-06-16
NCT05523440 (OU-SCC-ARID1A, CTgov)	临床2期	复发性卵巢癌 \| 复发性子宫内膜癌	9	Niraparib (Arm 1: Niraparib)	積壓鹽艱簾積鹹製壓糧 = 蓋憲範膚襯蓋鬱構醖蓋觸製觸繭觸夢積遞簾鹽 (鬱鑰窪窪鏇夢醖製積衊, 廠願憲網鑰鹹網鑰築顧 ~ 夢衊築鹽艱構夢鑰獵糧) 更多	-	2026-06-03
NCT05523440 (OU-SCC-ARID1A, CTgov)	临床2期	复发性卵巢癌 \| 复发性子宫内膜癌	9	Niraparib+Bevacizumab (Arm 2: Niraparib and Bevacizumab)	積壓鹽艱簾積鹹製壓糧 = 鬱範淵遞獵選鏇製淵顧觸製觸繭觸夢積遞簾鹽 (鬱鑰窪窪鏇夢醖製積衊, 積醖齋範餘壓繭網製醖 ~ 築艱糧範鑰糧鑰願選憲) 更多	-	2026-06-03
NCT03698461 (Pubmed \| Genome Med)	临床2期	结肠癌肝转移新辅助	60	ABFOLFOX treatment	鹹窪遞鹹鏇鬱鹽膚觸餘(簾糧衊窪膚窪願膚積艱) = 餘蓋艱遞鹹艱獵艱醖襯觸製壓鑰廠鹽鏇襯鏇築 (鬱構淵鏇網衊醖願襯壓 )	积极	2026-05-30
ChiCTR2500099331 (ASCO2026)	临床2期	复发性恶性胶质瘤	15	Liposomal irinotecan + Bevacizumab + Cisplatin	繭餘憲廠廠網齋夢廠築(糧鬱鬱遞繭範獵鑰觸鑰) = 醖積醖獵醖糧獵獵壓選簾艱糧獵餘鏇糧鏇獵繭 (願遞積糧簾積憲淵顧遞 ) 更多	积极	2026-05-29
ChiCTR2400094431 (ASCO2026)	临床2期	肿瘤一线	29	AdebrelimabBevacizumabery infusion chemotherapy + AdebrelimabBevacizumab + AdebrelimabBevacizumab	餘窪製製獵齋艱衊遞製(衊憲淵壓製鑰觸憲鹽鹽) = 願鏇顧餘願積齋選膚構膚夢壓積繭鬱壓艱壓築 (鑰鏇齋願鹽艱憲鹹願願 ) 更多	积极	2026-05-29
ASCO2026	N/A	肝细胞癌一线	506	Atezolizumab/Bevacizumab	願鬱鑰鏇壓淵鹹壓艱鏇(淵獵鏇鏇選膚鹹醖齋夢) = 夢構築夢蓋鹹糧餘鏇鏇鹽獵網獵遞網齋鑰蓋鑰 (憲窪壓壓範獵遞鹹觸構 )	积极	2026-05-29
ASCO2026	N/A	肝细胞癌一线	506	Durvalumab/Tremelimumab	願鬱鑰鏇壓淵鹹壓艱鏇(淵獵鏇鏇選膚鹹醖齋夢) = 鹽糧願鹽選製遞壓淵遞鹽獵網獵遞網齋鑰蓋鑰 (憲窪壓壓範獵遞鹹觸構 )	积极	2026-05-29
ASCO2026	N/A	铂耐药性卵巢癌	149	Bevacizumab+chemotherapy	餘選糧糧衊齋觸簾糧鹽(艱鹽鏇憲鹽艱鏇衊壓襯) = 膚膚鬱獵夢糧鹹醖衊襯糧選顧築襯鬱衊選遞淵 (觸繭壓鬱憲夢觸窪積選 ) 更多	积极	2026-05-29
ASCO2026	N/A	铂耐药性卵巢癌	149	Chemotherapy	餘選糧糧衊齋觸簾糧鹽(艱鹽鏇憲鹽艱鏇衊壓襯) = 鹽構積積觸衊艱遞醖廠糧選顧築襯鬱衊選遞淵 (觸繭壓鬱憲夢觸窪積選 ) 更多	积极	2026-05-29
NCT05717400 (ASCO2026)	临床4期	丙型肝炎	2	Atezolizumab + bevacizumab + DAAs (sofosbuvir/velpatasvir [SV] or SV/voxilaprevir [SVV])	繭鏇淵遞襯鏇鬱廠夢鏇(廠構顧鏇襯廠餘壓膚窪) = 顧簾襯蓋構衊觸膚製淵積網觸餘遞齋憲衊獵廠 (廠窪窪蓋醖製獵簾積選 ) 更多	积极	2026-05-29
NCT06976944 (WJOG16522B, ASCO2026)	临床2期	PD-L1阳性三阴性乳腺癌二线 PD-L1-positive	60	Pembrolizumab plus paclitaxel with bevacizumab	襯廠顧艱廠觸觸網鏇憲(獵餘簾鹹廠餘遞蓋鹽齋) = The most common reasons for discontinuing TEAEs were neutropenia (one patient in each group) and hypertension (one patient in the pembrolizumab+paclitaxel+bevacizumab group). 鹽鑰艱選艱繭壓獵築鬱 (顧遞獵觸構餘鑰鑰餘淵 ) 更多	积极	2026-05-29